Bortezomib Side Effects: Safety Signals and Warnings
Bortezomib safety concerns are compound-specific. The main listed side effects are Peripheral neuropathy (sensory and motor), Thrombocytopenia (cyclical, platelet nadir at day 11), and Nausea and diarrhea. The main warning signals are Peripheral neuropathy - dose modification required with new onset or worsening, Thrombocytopenia - monitor platelet counts regularly, and Herpes zoster prophylaxis recommended (acyclovir).
Direct Answer
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- Multiple myeloma (newly diagnosed and relapsed), mantle cell lymphoma, proteasome biology research
Reported Side Effects
- Peripheral neuropathy (sensory and motor)
- Thrombocytopenia (cyclical, platelet nadir at day 11)
- Nausea and diarrhea
- Fatigue
- Herpes zoster reactivation
Warnings
- Peripheral neuropathy - dose modification required with new onset or worsening
- Thrombocytopenia - monitor platelet counts regularly
- Herpes zoster prophylaxis recommended (acyclovir)
- Hypotension - use caution with antihypertensives
- Pulmonary toxicity reported rarely
Known or Plausible Interactions
- CYP3A4 inhibitors (ketoconazole increases bortezomib exposure)
- CYP3A4 inducers (rifampin decreases bortezomib levels)
- Oral hypoglycemics (blood glucose fluctuations reported)
- Antihypertensives (additive hypotension risk)
Regulatory Context
FDA-approved for multiple myeloma (2003) and mantle cell lymphoma (2006). Available by prescription only. Marketed as Velcade by Takeda. Generic versions available.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Multiple Myeloma Treatment (Level A), Mantle Cell Lymphoma (Level A), Peripheral Neuropathy (Level A), and Bone Health Improvement (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Bortezomib Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/bortezomib-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.